In vitro, PRMT5 inhibition increased markers of DNA damage in breast and ovarian cancer cell lines, and combination with PARP inhibitor produced additive to synergistic growth inhibition in both cancer cell lines and 3D clonogenic patient derived xenograft (PDX) models. Here, PRMT5 is linked to ovarian carcinoma.